149 related articles for article (PubMed ID: 36272639)
21. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
Zhu X; Xu J; Cai H; Lang J
J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
[TBL] [Abstract][Full Text] [Related]
22. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
23. Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after "IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer".
Abiko K; Hamanishi J; Matsumura N; Mandai M
Br J Cancer; 2023 Feb; 128(3):461-467. PubMed ID: 36068276
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96.
Fauci JM; Sabbatino F; Wang Y; Londoño-Joshi AI; Straughn JM; Landen CN; Ferrone S; Buchsbaum DJ
Gynecol Oncol; 2014 Jan; 132(1):203-10. PubMed ID: 24216048
[TBL] [Abstract][Full Text] [Related]
25. MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer.
Deng M; Wu D; Zhang Y; Jin Z; Miao J
Gynecol Oncol; 2021 Jul; 162(1):190-199. PubMed ID: 33875234
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer.
Wahba J; Natoli M; Whilding LM; Parente-Pereira AC; Jung Y; Zona S; Lam EW; Smith JR; Maher J; Ghaem-Maghami S
Cancer Immunol Immunother; 2018 Nov; 67(11):1753-1765. PubMed ID: 30167862
[TBL] [Abstract][Full Text] [Related]
27. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
[No Abstract] [Full Text] [Related]
28. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.
Liang Y; Wang W; Zhu X; Yu M; Zhou C
Sci Rep; 2022 Jun; 12(1):9619. PubMed ID: 35688951
[TBL] [Abstract][Full Text] [Related]
29. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
30. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
Mendes AA; Lu J; Kaur HB; Zheng SL; Xu J; Hicks J; Weiner AB; Schaeffer EM; Ross AE; Balk SP; Taplin ME; Lack NA; Tekoglu E; Maynard JP; De Marzo AM; Antonarakis ES; Sfanos KS; Joshu CE; Shenderov E; Lotan TL
Cancer; 2022 Jun; 128(12):2269-2280. PubMed ID: 35333400
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-326 attenuates immune escape and prevents metastasis in lung adenocarcinoma by targeting PD-L1 and B7-H3.
Shao L; He Q; Wang J; He F; Lin S; Wu L; Gao Y; Ma W; Dong J; Yang X; Li F
Cell Death Discov; 2021 Jun; 7(1):145. PubMed ID: 34131111
[TBL] [Abstract][Full Text] [Related]
32. Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria.
Xie XQ; Yang Y; Wang Q; Liu HF; Fang XY; Li CL; Jiang YZ; Wang S; Zhao HY; Miao JY; Ding SS; Liu XD; Yao XH; Yang WT; Jiang J; Shao ZM; Jin G; Bian XW
Cell Res; 2023 Mar; 33(3):215-228. PubMed ID: 36627348
[TBL] [Abstract][Full Text] [Related]
33. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.
Zhu X; Lang J
J Gynecol Oncol; 2017 Sep; 28(5):e64. PubMed ID: 28657225
[TBL] [Abstract][Full Text] [Related]
34. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA
J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021
[TBL] [Abstract][Full Text] [Related]
35. PD-L1, B7-H3 and VISTA are highly expressed in gestational trophoblastic neoplasia.
Zong L; Zhang M; Wang W; Wan X; Yang J; Xiang Y
Histopathology; 2019 Sep; 75(3):421-430. PubMed ID: 31013360
[TBL] [Abstract][Full Text] [Related]
36. Co-deficiency of B7-H3 and B7-H4 identifies high CD8 + T cell infiltration and better prognosis in pancreatic cancer.
Si S; Wang L; Cao H; Xu Y; Zhan Q
BMC Cancer; 2022 Feb; 22(1):211. PubMed ID: 35219310
[TBL] [Abstract][Full Text] [Related]
37. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody.
Ma W; Ma J; Ma P; Lei T; Zhao M; Zhang M
Cancer Med; 2018 Oct; 7(10):5167-5177. PubMed ID: 30253078
[TBL] [Abstract][Full Text] [Related]
38. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.
Niu N; Shen W; Zhong Y; Bast RC; Jazaeri A; Sood AK; Liu J
Hum Pathol; 2021 Jul; 113():20-27. PubMed ID: 33887301
[TBL] [Abstract][Full Text] [Related]
39. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
Abiko K; Matsumura N; Hamanishi J; Horikawa N; Murakami R; Yamaguchi K; Yoshioka Y; Baba T; Konishi I; Mandai M
Br J Cancer; 2015 Apr; 112(9):1501-9. PubMed ID: 25867264
[TBL] [Abstract][Full Text] [Related]
40. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
